disease free survival
Results: Docetaxel-carboplatin-trastuzumab regimen improved disease free survival (DFS), with the rate of 1 year, 2 year, 3 year, 4 year and 5 year DFS of 100%, 100%, 100%, 92% and 83.
Results : Docetaxel-carboplatin-trastuzumab regimen improved disease free survival ( DFS ), with the rate of 1 year, 2 year, 3 year, 4 year and 5 year DFS of 100%, 100%, 100%, 92% and 83 .